China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...

Prince Harry has been having great fun in Vancouver with his wife Meghan Markle - but he has been dealt a difficult blow as ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The move up comes as the S&P 500 (SNPINDEX: ^GSPC) ...

Only time will tell what is next in the landscape of tobacco and nicotine regulation from the White House and the FDA.

A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial. Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025. SEATTLE and VANCOUVER, British C ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Grace Therapeutics intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund pre-commercial development of GTx-104, a clinical stage, novel, ...

Ipratropium bromide nasal solution (nasal spray), 0.03% gives symptomatic relief in cases associated with allergic and ...

The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.